

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

Antonin Levy^{a,b} Carlos Gomez-Roca^a Christophe Massard^a David Planchard^c
Laurence Albiges^a Ratislav Bahleda^a Céline Bourgier^{a,b} Eric Deutsch^{a,b}
Jean Charles Soria^{a,c} Benjamin Besse^{a,c}

^aSITEP (Service des Innovations Thérapeutiques Précoce), Department of Medicine,

^bDepartment of Radiation Oncology,

^cLung Cancer Unit, Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Fig. 1. The PFS times in 70 NSCLC patients treated in phase I trials were similar to those in their prior lines.





Fig. 2. OS in 70 pretreated NSCLC patients treated in phase I trials (**a**) and according to ECOG PS score (**b**).

((a))



((b))

